In this video, healthcare bureau chief Brenton Flynn talks with analyst Max Macaluso about two biotech stocks, Zalicus and Geron, that dropped significantly on Monday after poor clinical trial results were released.
Zalicus, a biotech that develops drugs for the treatment of pain and inflammatory diseases, announced that it will halt the development of its rheumatoid arthritis drug, Synavive. Geron, a company focused on discovering new treatments for cancer, canceled its phase 2 imetelstat clinical trial for the treatment of breast cancer. Geron also indicated that it will not bring imetelstat to phase 3 trials for the treatment of non-small-cell lung cancer.
This is disappointing news for investors, but stories like these illustrate the binary nature of biotech investments. One of the best ways to absorb these market fluctuations is to balance your portfolio with stable stocks that can help you build long-term wealth. In our free report "3 Stocks That Will Help You Retire Rich," we reveal companies that you can integrate into your wealth-building strategies. Grab your copy today by clicking here -- it's totally free.
The article Why Zalicus and Geron Shares Plunged originally appeared on Fool.com.
Brenton Flynn has no positions in the stocks mentioned above. Max Macaluso has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Motley Fool newsletter services recommend Covidien. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.